Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Arcturus Therapeutics’ rating from “strong sell” to “sell,” while Weiss Ratings maintained its “sell (D-)” assessment. Despite this, MarketBeat’s analyst consensus remains “Moderate Buy,” with an average price target of $24.25.
• ARCT shares opened at $7.41, with a market capitalization of approximately $210.6 million and a 52-week range of $5.50 to $24.17. The company reported a quarterly loss of $0.84 per share, better than the expected $1.00 loss, but revenue of $2.96 million fell short of estimates.
• Institutional investors own 94.54% of Arcturus shares. The clinical-stage biotech is developing mRNA medicines and vaccines, including candidates targeting phenylketonuria and COVID-19.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Sunday.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $24.25.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $7.41 on Friday. The firm has a market cap of $210.59 million, a P/E ratio of -2.24 and a beta of 2.39. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $24.17. The firm has a 50-day simple moving average of $6.77 and a 200-day simple moving average of $7.38.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 44.42% and a negative net margin of 317.62%.The business had revenue of $2.96 million for the quarter, compared to analysts' expectations of $3.11 million. On average, research analysts predict that Arcturus Therapeutics will post -3.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently bought and sold shares of ARCT. Osaic Holdings Inc. lifted its position in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 738 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 2,586 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Arcturus Therapeutics in the 4th quarter valued at $64,000. Intech Investment Management LLC acquired a new stake in Arcturus Therapeutics during the 4th quarter worth $70,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of Arcturus Therapeutics by 65.1% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company's stock worth $73,000 after buying an additional 4,737 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source